Critical threshold cerebral hypoperfusion causes Alzheimer's disease?

被引:123
作者
de la Torre, JC [1 ]
机构
[1] Univ New Mexico Hosp, Div Neurosurg, Albuquerque, NM 87131 USA
关键词
Alzheimer's disease; cerebral hypoperfusion; aging; capillaries; energy metabolism;
D O I
10.1007/s004010051044
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
After nearly a century of inquiry, the cause of Alzheimer's disease (AD) remains to be found. In this review, basic and clinical evidence is presented that assembles and hypothetically explains most of the key pathologic events associated with the development of AD. These pathologic events are triggered in AD by an impaired cerebral perfusion originating in the microvasculature which affects the optimal delivery of glucose and oxygen and results in a breakdown of metabolic energy pathways in brain cells such as in the biosynthetic and synaptic pathways. We propose that two factors need to be present before cognitive dysfunction and neurodegeneration is expressed in AD brain: advanced aging, and the presence of a condition that lowers cerebral perfusion. The first factor introduces a normal but potentially menacing process that lowers cerebral blood flow in correlation to increased aging, while the second factor adds a crucial element which further lowers brain perfusion and establishes the heterogeneic disease profile observed in AD patients. These two factors will lead to a critical threshold cerebral hypoperfusion. Critical threshold cerebral hypoperfusion is a self-perpetuating, contained and progressive circulatory insufficiency that will destabilize neurons, synapses, neurotransmission and cognitive function, creating in its wake a neurodegenerative process characterized by the formation of senile plaques, neurofibrillary tangles, and amyloid angiopathy. A discussion of target therapy based on the proposed pathogenesis of AD is also briefly reviewed.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 70 条
  • [1] Abdollahian NP, 1998, CYTOCHROME OXIDASE IN NEURONAL METABOLISM AND ALZHEIMER'S DISEASE, P233
  • [2] ANATOMICAL MAPPING OF GLUCOSE TRANSPORTER PROTEIN AND PYRUVATE-DEHYDROGENASE IN RAT-BRAIN - AN IMMUNOGOLD STUDY
    BAGLEY, PR
    TUCKER, SP
    NOLAN, C
    LINDSAY, JG
    DAVIES, A
    BALDWIN, SA
    CREMER, JE
    CUNNINGHAM, VJ
    [J]. BRAIN RESEARCH, 1989, 499 (02) : 214 - 224
  • [3] Bartenstein P, 1997, J NUCL MED, V38, P1095
  • [4] THE FLUORODEOXYGLUCOSE F-18 SCAN IN ALZHEIMERS-DISEASE AND MULTI-INFARCT DEMENTIA
    BENSON, DF
    KUHL, DE
    HAWKINS, RA
    PHELPS, ME
    CUMMINGS, JL
    TSAI, SY
    [J]. ARCHIVES OF NEUROLOGY, 1983, 40 (12) : 711 - 714
  • [5] BLASS JP, 1993, NEUROLOGY, V43, pS25
  • [6] BOTET JP, 1992, STROKE, V23, P1556
  • [7] BUEE L, 1994, ACTA NEUROPATHOL, V87, P469
  • [8] DIFFERENCES IN THE EFFECTS IN THE NEWBORN PIGLET OF VARIOUS NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON CEREBRAL BLOOD-FLOW BUT NOT ON CEREBROVASCULAR PROSTAGLANDINS
    CHEMTOB, S
    BEHARRY, K
    BARNA, T
    VARMA, DR
    ARANDA, JV
    [J]. PEDIATRIC RESEARCH, 1991, 30 (01) : 106 - 111
  • [9] Regional cerebral blood flow and cerebrovascular risk factors in the elderly population
    Claus, JJ
    Breteler, MMB
    Hasan, D
    Krenning, EP
    Bots, ML
    Grobbee, DE
    Van Swieten, JC
    Van Harskamp, F
    Hofman, A
    [J]. NEUROBIOLOGY OF AGING, 1998, 19 (01) : 57 - 64
  • [10] APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS
    DAVIGNON, J
    GREGG, RE
    SING, CF
    [J]. ARTERIOSCLEROSIS, 1988, 8 (01): : 1 - 21